Expert NetworkExpert InterviewNVS

Slingshot members are talking to an expert! The topic is:

Discussing the Potential of Using Novartis’s Pluvicto Before Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Executed on:Mar 26, 2026 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: New Mexico Cancer Center
  • Medical Director of Radiation Oncology at the New Mexico Cancer Center & Assistant Professor of Medicine and the University of New Mexico.
  • Treats 7 patients per month with mCRPC and has 6 patients receiving Pluvicto every month.
  • Research and clinical interest in radiation oncology.

Interview Goal

The goal of this interview with a radiation oncologist is to discuss the standard of care and the real-world evidence supporting the earlier use of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) to treat metastatic castration-resistant prostate cancer.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.